Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times ...

It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with ...

AstraZeneca outperforms markets YTD amid eased concerns, China clarity, minimal US tariff impact, and attractive valuations.

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a ...